<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lidocaine and prilocaine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lidocaine and prilocaine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lidocaine and prilocaine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11780" href="/d/html/11780.html" rel="external">see "Lidocaine and prilocaine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12553" href="/d/html/12553.html" rel="external">see "Lidocaine and prilocaine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F188755"><span class="drugH1">Brand Names: US</span>
<ul>
<li>AgonEaze;</li>
<li>Anodyne LPT;</li>
<li>DermacinRx Empricaine;</li>
<li>DermacinRx Prizopak;</li>
<li>EmReal;</li>
<li>Lido BDK;</li>
<li>Lidopril XR [DSC];</li>
<li>Lidopril [DSC];</li>
<li>Livixil Pak;</li>
<li>Oraqix;</li>
<li>Prikaan;</li>
<li>Prikaan Lite;</li>
<li>Prilolid [DSC];</li>
<li>Prilovix;</li>
<li>Prizotral II;</li>
<li>Relador Pak</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912122"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>EMLA;</li>
<li>Oraqix</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F188773"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Local Anesthetic</li></ul></div>
<div class="block doa drugH1Div" id="F188758"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb479ed7-37f7-495a-84af-a27b520b54df">Anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Anesthetic:</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Cream (intact skin): <b>Note:</b> Apply a thick layer to intact skin and cover with an occlusive dressing. Dermal analgesia can be expected to increase for up to 3 hours under occlusive dressing and persist for 1 to 2 hours after removal of the cream.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>US labeling:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Minor dermal procedures (eg, IV cannulation or venipuncture):</i> Apply 2.5 g (<sup>1</sup>/<sub>2</sub> of the 5 g tube) over 20 to 25 cm<sup>2</sup> of skin surface area) for at least 1 hour</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Major dermal procedures (eg, more painful dermatological procedures involving a larger skin area such as split thickness skin graft harvesting):</i> Apply 2 g per 10 cm<sup>2</sup> of skin and allow to remain in contact with the skin for at least 2 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adult male genital skin (eg, pretreatment prior to local anesthetic infiltration):</i> Apply 1 g per 10 cm<sup>2</sup> to the skin surface for 15 minutes. Local anesthetic infiltration should be performed immediately after removal of cream.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Adult female genital mucous membranes: </i>Minor procedures (eg, removal of condylomata acuminata, pretreatment for local anesthetic infiltration): Apply 5 to 10 g for 5 to 10 minutes. The local anesthetic infiltration or procedure should be performed immediately after removal of cream.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Canadian labeling:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Minor dermal procedures (eg, IV cannulation, venipuncture, surgical or laser treatment):</i> Apply 2 g (~<sup>1</sup>/<sub>2</sub> of the 5 g tube) over ~13.5 cm<sup>2</sup> for at least 1 hour but no longer than 5 hours</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Major dermal procedures (eg, split-skin grafting):</i> 1.5 to 2 g per 10 cm<sup>2</sup> (maximum: 60 g per 400 cm<sup>2</sup>) for at least 2 hours but no longer than 5 hours</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Genital mucosa (eg, surgical procedures ≤10 minutes such as localized wart removal, and prior to local anesthetic infiltration):</i> Apply 2 g (~<sup>1</sup>/<sub>2</sub> of 5 g tube) per lesion (maximum: 10 g) for 5 to 10 minutes. Initiate procedure immediately after removing cream.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Leg ulcers (eg, mechanical cleansing/surgical debridement):</i> Apply ~1 to 2 g per 10 cm<sup>2 </sup>(maximum: 10 g) for at least 30 minutes and up to 60 minutes for necrotic tissue that is more difficult to penetrate. Initiate procedure immediately after removing cream.</p>
<p style="text-indent:-2em;margin-left:2em;">Periodontal gel: Apply on gingival margin around selected teeth using the blunt-tipped applicator included in package. Wait 30 seconds, then fill the periodontal pockets using the blunt-tipped applicator until gel becomes visible at the gingival margin. Wait another 30 seconds before starting treatment. May reapply; maximum recommended dose: One treatment session: 5 cartridges (8.5 g)</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch [Canadian product]: Minor procedures (eg, needle insertion): Apply 1 or more patches to intact skin surface area &lt;10 cm<sup>2</sup> for at least 1 hour (maximum application time: 5 hours)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990465"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer labeling. Lidocaine and prilocaine primarily undergo hepatic metabolism and their pharmacokinetics are not expected to be changed significantly in renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50987700"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Smaller areas of treatment are recommended for patients with severe hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F188759"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Initiate at the low end of the dosing range; use with caution.</p></div>
<div class="block dop drugH1Div" id="F188767"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12553" href="/d/html/12553.html" rel="external">see "Lidocaine and prilocaine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Smaller areas of treatment recommended in smaller or debilitated patients or patients with impaired elimination; decreasing the duration of application may decrease analgesic effect, however maximum application duration times should not be exceeded.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="118e6d95-3b78-4297-8b1c-9f4ead3aecfe">Minor dermal procedures; anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Minor dermal procedures (eg, IV access, venipuncture, IM injection); anesthetic: Note: </b>General dosing information provided, dose should be individualized based on procedure and area to be anesthetized.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Topical:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;5 kg: Apply ≤1 g per 10 cm<sup>2</sup> area; cover with an occlusive dressing for usual duration of application of 60 minutes prior to procedure. Maximum dosing information for a 24-hour period: Maximum total dose (for all sites combined): 1 g; maximum application area: 10 cm<sup>2</sup>; maximum application time: 1 hour.</p>
<p style="text-indent:-2em;margin-left:6em;">5 kg to 10 kg: Apply 1 to 2 g per 10 cm<sup>2</sup> area; cover with occlusive dressing for at least 60 minutes. Maximum dosing information for a 24-hour period: Maximum total dose (for all sites combined): 2 g; maximum application area: 20 cm<sup>2</sup>; maximum application time: 4 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;10 kg to 20 kg: Apply 1 to 2 g per 10 cm<sup>2</sup> area; cover with occlusive dressing for at least 60 minutes. Maximum dosing information for a 24-hour period: Maximum total dose (for all sites combined): 10 g; maximum application area: 100 cm<sup>2</sup>; maximum application time: 4 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 kg: Apply 1 to 2 g per 10 cm<sup>2</sup> area; cover with occlusive dressing for at least 60 minutes. Maximum dosing information for a 24-hour period: Maximum total dose (for all sites combined): 20 g; maximum application area: 200 cm<sup>2</sup>; maximum application time: 4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Apply 2.5 g of cream (<sup>1</sup>/<sub>2</sub> of the 5 g tube) over 20 to 25 cm<sup>2</sup> of skin surface area for at least 1 hour.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5e435e59-ae5b-49dc-a6f4-8c76c7a85804">Major dermal procedures; anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major dermal procedures (eg, more painful dermatological procedures involving a larger skin area such as split thickness skin graft harvesting); anesthetic: </b>Adolescents: Topical: Apply 2 g of cream per 10 cm<sup>2</sup> of skin and allow to remain in contact with the skin for at least 2 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a75e8b8-330c-4900-8186-2748d84f022a">Male genital skin, pretreatment prior to local anesthetic infiltration</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Male genital skin, pretreatment prior to local anesthetic infiltration:</b> Adolescents: Topical: Apply 1 g per 10 cm<sup>2</sup> to the skin surface for 15 minutes. Local anesthetic infiltration should be performed immediately after removal of cream.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1018407b-321a-44c5-9c34-77ce323120c3">Female genital mucous membranes, anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Female genital mucous membranes, anesthetic:</b> Minor procedures (eg, removal of condylomata acuminata, pretreatment for local anesthetic infiltration): Adolescents: Topical: Apply 5 to 10 g of cream for 5 to 10 minutes.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f660e8c9-a220-4874-9ae2-67c63fe9f04b">Local anesthetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Local anesthetic:</b> General dosing information provided, dose should be individualized based on procedure and area to be anesthetized.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch [Canadian product]: <b>Note:</b> Dosing is based on child's age and weight; if a patient is ≥3 months and is smaller than weight requirement, defer to maximum dose for the patient's weight.</p>
<p style="text-indent:-2em;margin-left:6em;">Apply patch(es) to skin area(s) &lt;10 cm<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &lt;3 months or &lt;5 kg: Topical: Apply 1 patch and leave on for ~1 hour; maximum dose: 1 patch; maximum application time: 1 hour. Do not apply more than 1 patch at same time.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥3 months and &gt;5 kg: Topical: Apply 1 to 2 patches for ~1 hour; maximum dose: 2 patches; maximum application time: 4 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≤6 years and &gt;10 kg: Topical: Apply 1 or more patches for minimum of 1 hour; maximum dose: 10 patches; maximum application time: 5 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥7 years and &gt;20 kg and Adolescents: Topical: Apply 1 or more patches for a minimum of 1 hour; maximum dose: 20 patches; maximum application time: 5 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117793"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer labeling. Lidocaine and prilocaine primarily undergo hepatic metabolism and their pharmacokinetics are not expected to be changed significantly in renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51117794"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Smaller areas of treatment are recommended for patients with severe hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F188732"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cream:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (41% to 56%; including application-site burning [17%], application-site edema [6% to 10%], application-site erythema [21% to 30%], application-site local purpuric or petechial reaction, application-site pruritus [2%], application-site rash [&lt;1%], local alterations in temperature sensations [7%], local skin hyperpigmentation, localized blanching [37%])</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Genitourinary: Blistering of foreskin</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Periodontal gel:</b></p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Local: Application-site reaction (13%, includes application-site edema, application-site erythema, application-site irritation, application-site pain, application-site vesicles, oral mucosa ulcer, oral paresthesia, periodontal abscess)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Bitter taste (2%), nausea (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (1%), respiratory tract infection (1%)</p></div>
<div class="block coi drugH1Div" id="F188743"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to local anesthetics of the amide type or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Congenital or idiopathic methemoglobinemia.</p>
<p style="text-indent:-2em;margin-left:4em;">Cream and patch only: Infants ≤12 months of age who require treatment with methemoglobin-inducing agents; preterm infants (gestational age &lt;37 weeks); procedures requiring large amounts over a large body area that are not conducted in a facility with health care professionals trained in the diagnosis and management of dose-related toxicity and other acute emergencies, and with appropriate resuscitative treatments and equipment.</p></div>
<div class="block war drugH1Div" id="F188729"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Allergic and anaphylactic reactions may occur. Patients allergic to paraaminobenzoic acid derivatives (eg, procaine, tetracaine, benzocaine) have not shown cross sensitivity to lidocaine and/or prilocaine; use with caution in patients with a history of drug sensitivities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants &lt;6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Atopic dermatitis: Use with caution; rapid and greater absorption through the skin is observed in these patients; a shorter application time should be used.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe impairment of impulse initiation and conduction in the heart (eg, grade II and III AV block, pronounced bradycardia).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with G6PD may be more susceptible to drug-induced methemoglobinemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment; risk of increased systemic exposure. Smaller treatment area may be required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acutely ill patients: Use with caution in acutely ill; smaller treatment area may be required consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; smaller treatment area may be required consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in elderly patients; smaller treatment area may be required consistent with age and physical status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Periodontal gel: Do not use with standard dental syringes; only use with the supplied blunt-tipped applicator.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Although the incidence of systemic adverse reactions with use of the cream is very low, caution should be exercised, particularly when applying over large areas and leaving on for longer than 2 hours. When used prior to cosmetic or medical procedures, the smallest amount of cream necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heartbeats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for a prolonged time, or have used wraps/dressings to cover the skin following application. Do not apply to broken or inflamed skin, open wounds, or near the eyes. Avoid use in situations where penetration or migration past the tympanic membrane into the middle ear is possible; ototoxicity has been observed in animal studies. Avoid inadvertent trauma to the treated area (eg, scratching, rubbing, exposure to extreme hot or cold temperatures) until complete sensation has returned.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878519"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Adjust dose in patients with increased risk for methemoglobinemia; use smaller areas for application in small children (especially infants &lt;3 months of age). In small infants and children, an occlusive bandage may prevent the child from placing the cream in his/her mouth or smearing the cream on the eyes.</p></div>
<div class="block foc drugH1Div" id="F188738"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Cream, topical:</p>
<p style="text-indent:-2em;margin-left:4em;">AgonEaze: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">Anodyne LPT: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">DermacinRx Empricaine: Lidocaine 2.5% and prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">DermacinRx Prizopak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">Lido BDK: Lidocaine 2.5% and prilocaine 2.5% (5 g)</p>
<p style="text-indent:-2em;margin-left:4em;">Lidopril: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing] [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Lidopril XR: Lidocaine 2.5% and prilocaine 2.5% (2 x 30 g) [packaged with occlusive dressing] [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Livixil Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">Prikaan: Lidocaine 2.5% and Prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">Prikaan Lite: Lidocaine 2.5% and Prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">Prilolid: Lidocaine 2.5% and prilocaine 2.5% (1 x 30 g) [packaged with occlusive dressing] [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;">Prilovix Versipac: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">Prizotral II: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) with lidocaine HCl 3.88% (85 g)</p>
<p style="text-indent:-2em;margin-left:4em;">Relador Pak: Lidocaine 2.5% and prilocaine 2.5% (3 x 30 g) [packaged with occlusive dressing]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Lidocaine 2.5% and prilocaine 2.5% (5 g, 30 g, 5800 g, 18,000 g)</p>
<p style="text-indent:-2em;margin-left:2em;">Gel, periodontal:</p>
<p style="text-indent:-2em;margin-left:4em;">Oraqix: Lidocaine 2.5% and prilocaine 2.5% (1.7 g)</p></div>
<div class="block geq drugH1Div" id="F188725"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes: Cream</p></div>
<div class="block fee drugH1Div" id="F188745"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Lidocaine-Prilocaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per gram): $1.84 - $1.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Aprizio Pak External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $2,025.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (CadiraMD External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $259.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lido BDK External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $249.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lidocaine-Prilocaine External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $49.58</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Lidotor External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $2,275.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Livixil Pak External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $1,743.37</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Prilo Patch External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5 &amp; 5% (per each): $4,623.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Relador Pak External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $1,651.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Relador Pak Plus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $1,675.86</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (SkyaDerm-LP External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5-2.5% (per each): $1,825.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52912123"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;margin-left:0em;margin-top:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Patch, transdermal:</p>
<p style="text-indent:-2em;margin-left:4em;">EMLA Patch: Lidocaine 2.5% and prilocaine 2.5% per patch (2s, 20s) [active contact surface area of each 1 g patch: 10 cm<sup>2</sup>; surface area of entire patch: 40 cm<sup>2</sup>]</p></div>
<div class="block adm drugH1Div" id="F188740"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream: For external use only. Avoid application to open wounds or near the eyes. Avoid use in situations where penetration or migration past the tympanic membrane into the middle ear is possible. In small infants and children, observe patient to prevent accidental ingestion of cream or dressing. To obtain 1 g of cream, squeeze narrow strip ~1.5 inches long and 0.2 inches wide from tube. Repeat as necessary to obtain quantity needed for dose (eg, 2 strips = 2 g dose). Apply a thick layer of cream to designated site of intact skin. Cover site with occlusive dressing. Mark the time on the dressing. Allow at least 1 hour (mild dermatologic procedures) or at least 2 hours (major dermal procedures) for optimum therapeutic effect. Remove the dressing and wipe off excess cream (gloves should be worn). Smaller areas of treatment are recommended for small children, debilitated patients, or patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Periodontal gel: Make sure gel is in the liquid form before administration. If semisolid gel forms, refrigerate until becomes liquid again (do not freeze). Do not use dental cartridge warmers; heat will cause product to gel prematurely (product is a microemulsion that is intended to form a gel in the periodental pocket). Apply slowly and evenly on gingival margin around selected teeth using the provided blunt-tipped applicator. Wait 30 seconds, then fill the periodontal pockets using the blunt-tipped applicator until gel becomes visible at the gingival margin. Wait another 30 seconds before starting treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch [Canadian product]: Apply patch or patches to intact skin. Allow at least 1 hour for optimum therapeutic effect. After removing patch or patches, clean treated areas thoroughly prior to procedure.</p></div>
<div class="block admp drugH1Div" id="F52613156"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical:</p>
<p style="text-indent:-2em;margin-left:2em;">Cream: For external use only. Avoid application to open wounds or near the eyes. Avoid use in situations where penetration or migration past the tympanic membrane into the middle ear is possible. In small infants and children, observe patient to prevent accidental ingestion of cream or dressing. To obtain 1 g of cream, squeeze narrow strip ~1.5 inches long and 0.2 inches wide from tube. Repeat as necessary to obtain quantity needed for dose (eg, 2 strips = 2 g dose). Apply a thick layer of cream to designated site of intact skin. Cover site with occlusive dressing. Mark the time on the dressing. Allow at least 1 hour (mild dermatologic procedures) or at least 2 hours (major dermal procedures) for optimum therapeutic effect. Remove the dressing and wipe off excess cream (gloves should be worn). Smaller areas of treatment are recommended for small children, debilitated patients, or patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal patch [Canadian product]: Apply patch or patches to intact skin. After removing patch or patches, clean treated areas thoroughly prior to procedure.</p></div>
<div class="block use drugH1Div" id="F188739"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Topical anesthetic for use on normal intact skin to provide local analgesia; for use on genital mucous membranes for superficial minor surgery; and as pretreatment for infiltration anesthesia.</p>
<p style="text-indent:-2em;margin-left:4em;">Periodontal gel: Topical anesthetic for use in periodontal pockets during scaling and/or root planing procedures</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Topical anesthetic for use on intact skin in connection with: IV cannulation or venipuncture; superficial surgical procedures (eg, split skin grafting, electrolysis, removal of molluscum contagiosum); laser treatment for superficial skin surgery (eg, telangiectasia, port wine birthmarks, warts, moles, skin nodules, scar tissue); surgical procedures of genital mucosa (≤10 minutes) on small superficial localized lesions (eg, removal of condylomata by laser or cautery, biopsies); local infiltration anesthesia in genital mucous membranes; mechanical cleansing/debridement of leg ulcers; vaccination with measles-mumps-rubella (MMR), diphtheria-pertussis-tetanus-poliovirus (DPTP), <i>Haemophilus influenzae</i> b, and hepatitis B.</p>
<p style="text-indent:-2em;margin-left:4em;">Patch: Topical anesthetic for use on intact skin in connection with IV cannulation or venipuncture; vaccination with measles-mumps-rubella (MMR), diphtheria-pertussis-tetanus-poliovirus (DPTP), <i>Haemophilus influenzae</i> b, and hepatitis B.</p>
<p style="text-indent:-2em;margin-left:4em;">Periodontal gel: Topical anesthetic for use in periodontal pockets during scaling and/or root planing procedures</p></div>
<div class="block mst drugH1Div" id="F59056208"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:2em;">Anacin [Korea] may be confused with Anacin 3 brand name for acetaminophen [Taiwan]; Anacin 81 brand name for aspirin [Puerto Rico]; Anacin New brand name for acetaminophen/caffeine [India]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F188768"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F188733"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antiarrhythmic Agents (Class IB): Lidocaine (Topical) may enhance the adverse/toxic effect of Antiarrhythmic Agents (Class IB). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine.  Management: Avoid using any additional local anesthetics within 96 hours after insertion of the bupivacaine implant (Xaracoll) or bupivacaine and meloxicam periarticular solution (Zynrelef) or within 168 hours after subacromial infiltration (Posimir brand).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine (Liposomal): Local Anesthetics may enhance the adverse/toxic effect of BUPivacaine (Liposomal).  Management: Liposomal bupivacaine should not be administered with local anesthetics, but may be administered 20 minutes or more after lidocaine. Avoid all local anesthetics within 96 hours after administration of liposomal bupivacaine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Lidocaine (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Local Anesthetics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tilmanocept: Local Anesthetics may diminish the diagnostic effect of Technetium Tc 99m Tilmanocept.  Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F188746"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted with this combination. Lidocaine and prilocaine cross the placenta. Their use is not contraindicated during labor and delivery. Refer to individual agents.</p></div>
<div class="block brc drugH1Div" id="F188747"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Lidocaine is excreted in breast milk; excretion of prilocaine in breast milk unknown; however, systemic absorption following topical application is expected to be low. The manufacturer recommends that caution be exercised when administering to nursing women. Refer to individual agents.</p></div>
<div class="block mop drugH1Div" id="F20421842"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum methemoglobin before, during, and after use in neonates and infants up to 3 months of age. Consider ECG monitoring in patients treated with Class III antiarrhythmic drugs (eg, amiodarone).</p></div>
<div class="block pha drugH1Div" id="F188728"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Local anesthetic action occurs by stabilization of neuronal membranes and inhibiting the ionic fluxes required for the initiation and conduction of impulses</p></div>
<div class="block phk drugH1Div" id="F188742"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Cream:</p>
<p style="text-indent:-2em;margin-left:4em;">Onset of action: 1 hour (more rapid in genital mucosa: 5 to 10 minutes)</p>
<p style="text-indent:-2em;margin-left:6em;">Peak effect: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: 1 to 2 hours after removal; Genital mucosa: 15 to 20 minutes after application (range: 5 to 45 minutes)</p>
<p style="text-indent:-2em;margin-left:4em;">Absorption: Related to duration of application and area where applied</p>
<p style="text-indent:-2em;margin-left:6em;">3-hour application: 3.6% lidocaine and 6.1% prilocaine</p>
<p style="text-indent:-2em;margin-left:6em;">24-hour application: 16.2% lidocaine and 33.5% prilocaine</p>
<p style="text-indent:-2em;margin-left:2em;">Periodontal gel:</p>
<p style="text-indent:-2em;margin-left:4em;">Onset of action: ≤30 seconds</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: ~20 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F188748"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Emla | Xylocream</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Emla | Lidopril</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Emla | Oraqix parodontal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Emla | Numit | Oraqix</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Emprila | Skisia | Topican</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Emla | Romla</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Emla | Medicaina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Anesderm | Emla | Oraqix</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Compound lidocaine | Emla</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Anestecin | Emla | Maxtime</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anesderm | Emla | Emulus | Oraqix parodontal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Medicaina</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Anestil | Emla</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Emla | Lkpain kreem | Lpkain | Nulbia | Xylocream</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Emla | Ezanal | Pridocaine | Sabapremax</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anamap | Anestderma | Anesteal | Emla | Lidocaina/prilocaina ratiopharm</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lidocaine and prilocaine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Emla | Oraqix | Tapin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Anesderm | Emla | Lidocaine Prilocaine biogaran | Lidocaine/prilocaine zentiva | Prelic</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Denela | Emla | Nulbia | Oraqix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Emla | Funis | Xylocream</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Emla | Licarlo | Lidiprine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Li pri</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dolones | Emla | Estesia | Topsy</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Duo Caine | Emla</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Asthesia | Emlap | Prilido | Prilox | Primla | Prosil | Toplap</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Lidomax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Anesderm | Emla | Oraqix</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Anesderm | Emla</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Doctaine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anacin | Anecaine | Anes | Dermacain | Emao | Embicaine | Emla | Emloca | Emtukain | Ennerdis | Fcaine | J pro | Lescaine | Licaen plus | Licarlo | Lidopril | Lipril | Lowpain | Mamasin gold | Manecin | Manesin | Ms | Pencaine | Pliocan | Pricain | Pridocaine | Rejucellplus | Rocain | Wellscain plus | Wellscaine plus</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Emla | Prila</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Emla | Prilox</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Duocaine | Emla | Lipro | Racser</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Emla | Lidocaine/Prilocaine Teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Emla | Tapin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Emla | Numit</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Emla | Emlocaine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anesderm | Emla | Motti</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Agoneaze | Anodyne lpt | Aprizio pak ii | Dermacinrx empricaine | Dermacinrx prizopak | Emla | Empricaine ii | Leva set | Lido prilo caine pack | Lidocaine and prilocaine | Lidopril | Lidotor | Liprozonepak | Medolor pak | Nuvakaan ii | Oraqix | Prilolid | Prilovix | Prilovix plus | Prilovix ultralite | Prilovix ultralite plus | Prilovixil | Prizopak ii | Prizotral II | Skyaderm lp | Valladerm 90</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">EMLA | Mola | Numit | Xylocream</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Emla | Romla</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Akriol pro | Anesta A | Emla</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Emla | Ennla | Numit</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Denela | Emla | Lidokain/Prilokain Alternova | Lidokain/prilokain ebb | Oraqix | Tapin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Emla | Racser</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Anesderm | Emla</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dermacaine | Emla | Liprikaine | Racser</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Emla | Prilia</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Emla | Lidorin | Locpynol | Lpkain</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ella | Emla | Lidiprine | Lidopin | Lipredin | Liprido | Lipro | Lipry | Palocaine | Pancomal | Prilido | Primalido | Sincaine | Sopredin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Emla</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Emla | Xyloplus</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Emla | Topla</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22926175">
<a name="22926175"></a>American Academy of Pediatrics Task Force on Circumcision. Male circumcision. <i>Pediatrics</i>. 2012;130(3):e756-e785.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/22926175/pubmed" id="22926175" target="_blank">22926175</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  EMLA (lidocaine and prilocaine) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teligent.1">
<a name="Teligent.1"></a>Lidocaine and prilocaine [prescribing information]. Buena, NJ: Teligent Pharma Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oraqix.1">
<a name="Oraqix.1"></a>Oraqix (lidocaine and prilocaine) [prescribing information]. York, PA: Dentsply Pharmaceutical; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oraqix.2">
<a name="Oraqix.2"></a>Oraqix (lidocaine and prilocaine) [product monograph]. Woodbridge, Ontario, Canada: Dentsply Canada Limited; April 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29150457">
<a name="29150457"></a>Sharara-Chami R, Lakissian Z, Charafeddine L, Milad N, El-Hout Y. Combination analgesia for neonatal circumcision: a randomized controlled trial [published correction appears in <i>Pediatrics</i>. 2018.]. <i>Pediatrics</i>. 2017;140(6):e20171935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/29150457/pubmed" id="29150457" target="_blank">29150457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8523173">
<a name="8523173"></a>Taddio A, Shennan AT, Stevens B, et al, “Safety of Lidocaine-Prilocaine Cream in the Treatment of Preterm Neonates,” <i>J Pediatr</i>, 1995, 127(6):1002-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/8523173/pubmed" id="8523173" target="_blank">8523173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15662361">
<a name="15662361"></a>Weise KL and Nahata MC, "EMLA for Painful Procedures in Infants," <i>J Pediatr Health Care</i>, 2005, 19(1):42-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lidocaine-and-prilocaine-drug-information/abstract-text/15662361/pubmed" id="15662361" target="_blank">15662361</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9561 Version 275.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
